Brief Report: Inhibition of interleukin‐6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

Samson, M.; Audia, Sylvain; Janikashvili, Nona; Ciudad, Marion; Trad, Malika; Fraszczak, Jennifer; Ornetti, Paul; Maillefert, Jean-Françis; Miossec, Pierre; Bonnotte, Bernard

doi:10.1002/art.34477

Public

Brief Report: Inhibition of interleukin‐6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

Published in Arthritis & Rheumatism • Apr 5, 2012

Authors:

M. Samson

Sylvain Audia

Nona Janikashvili

Abstract

OBJECTIVE: From an immunologic standpoint, the mechanisms by which treatment with tocilizumab (TCZ), a humanized anti-interleukin-6 (anti-IL-6) receptor antibody, results in improvement in rheumatoid arthritis (RA) patients are still not fully understood. In vitro studies and studies in mouse models...

Subject

Tocilizumab

Medicine

Rheumatoid arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!